Anitha Rao, MD
Neurology · Mishawaka, INNPI 1396989976
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $118,348 of the $164,904 with a category attached, or 71.8%. Eisai Inc. accounts for 99.0% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2024 at $112,108 and has fallen 67.8% since, to $36,085 in 2025. Among neurology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $649.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$163K
- AbbVie$304
- Boston Scientific$285
- Acadia Pharmaceuticals Inc$245
- Argenx US, Inc.$172
- Neurocrine Biosciences, Inc.$71
- plus $622 from 20 others
What the payments were for
- Consulting fees$17,68811%
- Speaking & faculty fees$118,34872%
- Travel & lodging$23,70014%
- Food & beverage$5,1703%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 208 | $163,205 |
| AbbVie(2 entities) | 4 | $304 |
| Boston Scientific | 3 | $285 |
| Acadia Pharmaceuticals Inc | 2 | $245 |
| Argenx US, Inc. | 4 | $172 |
| Neurocrine Biosciences, Inc. | 4 | $71 |
| Banner Life Sciences, LLC | 3 | $66 |
| AstraZeneca | 3 | $55 |
| Lundbeck LLC | 2 | $53 |
| Teva Pharmaceuticals USA, Inc. | 2 | $49 |
| TG Therapeutics, Inc. | 2 | $48 |
| Gilead | 1 | $33 |
| Jazz Pharmaceuticals Inc. | 1 | $32 |
| Genentech USA, Inc. | 2 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Lilly USA, LLC | 2 | $30 |
| Neurelis, Inc. | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Amgen | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| EMD Serono, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Biogen | 1 | $17 |
| Abbott | 1 | $14 |
| Corium, LLC | 1 | $14 |
| Acorda Therapeutics, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$160,997
- WATCHMAN Access System$257
- NUPLAZID$245
- BOTOX$125
How this compares
$164,904 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Mishawaka
- Paula Toth-RussellMishawaka$80K
- Michael EnglertMishawaka$50K
- Francisco Gomez-DossiMishawaka$40K
- Kevin KristlMishawaka$35K
- William ConteMerrillville$1.2M
- Anthony SimchakLafayette$720K
- Mark JanickiLebanon$573K
- Ajay GuptaFort Wayne$411K
- Roderick WarrenEvansville$296K
- Ender AkanMunster$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.